Gary Leonhardt, MD
Addiction Medicine · Greenville, NCNPI 1538183942
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $79,825 of the $91,631 with a category attached, or 87.1%. 26 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 56.2% of the total. Reporting peaked in 2024 at $61,503 and has fallen 68.3% since, to $19,517 in 2025. Among addiction medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 506 payments — averaging $181.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$51K
- Almatica Pharma LLC$33K
- AbbVie$2K
- Johnson & Johnson$851
- Neurocrine Biosciences, Inc.$628
- Otsuka America Pharmaceutical, Inc.$540
- plus $4K from 20 others
What the payments were for
- Speaking & faculty fees$79,82587%
- Travel & lodging$2,0862%
- Food & beverage$9,57510%
- Education$1450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 86 | $51,455 |
| Almatica Pharma LLC | 44 | $32,549 |
| AbbVie(2 entities) | 111 | $1,841 |
| Johnson & Johnson | 35 | $851 |
| Neurocrine Biosciences, Inc. | 28 | $628 |
| Otsuka America Pharmaceutical, Inc. | 23 | $540 |
| E.r. Squibb & Sons, L.L.C. | 12 | $529 |
| Axsome Therapeutics, Inc. | 7 | $502 |
| Alkermes, Inc. | 22 | $481 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $429 |
| Indivior Inc. | 32 | $369 |
| Vanda Pharmaceuticals Inc. | 18 | $328 |
| Idorsia Pharmaceuticals US Inc | 10 | $246 |
| Avanir Pharmaceuticals, Inc. | 3 | $169 |
| Supernus Pharmaceuticals, Inc. | 12 | $136 |
| Lundbeck LLC | 7 | $114 |
| Braeburn Inc. | 4 | $90 |
| Eisai Inc. | 6 | $89 |
| Sunovion Pharmaceuticals Inc. | 9 | $67 |
| Corium, LLC | 3 | $62 |
| Jazz Pharmaceuticals Inc. | 3 | $43 |
| Merck | 3 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Brainsway USA Inc | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Azurity Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$91,631 in reported general payments places this provider in the 95th percentile of 42 addiction medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $87,731 |
| PerserisRisperidone | 19 | $56,837 |
| UzedyRisperidone | 11 | $35,347 |
| Invega SustennaPaliperidone Palmitate | 11 | $34,999 |
| RexultiBrexpiprazole | 19 | $29,328 |
| Loreev XrLorazepam | 33 | $18,807 |
| TrintellixVortioxetine Hydrobromide | 14 | $11,608 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $5,385 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 27 | $4,902 |
| Lurasidone Hcl | 26 | $4,601 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 42 | $4,176 |
| Lisdexamfetamine Dimesylate | 14 | $3,843 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 74 | $2,832 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 45 | $2,595 |
| Aripiprazole | 114 | $2,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $628 | $87,73111 claims |
| Indivior Inc.Perseris | $369 | $56,83719 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $51,455 | $35,34711 claims |
| Johnson & JohnsonInvega Sustenna | $851 | $34,99911 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $540 | $29,32819 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $32,549 | $19,16389 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $29 | $16,99227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 42 addiction medicine providers in North Carolina.
Other addiction medicine in Greenville
- Johnny WilliamsGreenville$3K
- David RyanGreenville$250
- Sevdalina Dabova-MissovaGreenville$0
- Bernard GottschalkWilmington$188K
- Hien NguyenApex$145K
- Emily Rayes-PrinceMonroe$69K
- Jonathan HallHendersonville$8K
- Barry WilliamsWinston-Salem$4K
- Heather ManosCharlotte$3K
- Sara KoenigCary$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.